Clinical trials · Pennsylvania
Lung Diseases clinical trials in Pennsylvania
We’re tracking 38 recruiting lung diseases studies with a site in Pennsylvania — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Bethlehem, PennsylvaniaAges 18 years+ - NCT06806592RecruitingPhase 3
Testing nerandomilast for lung scarring from rheumatic disease
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05746039RecruitingPhase 1/Phase 2
Testing semaglutide for advanced lung disease
This study checks whether semaglutide is safe and feasible for people with advanced lung diseases and higher body weight. It may help by testing a structured treatment approach, but it includes several health and safety limits.
Philadelphia, PennsylvaniaAges 18–80 - NCT06572384RecruitingPhase 3
Belimumab for lung scarring in autoimmune disease
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03683186Enrolling by invitationPhase 3
Long-term study of ralinepag for pulmonary hypertension
This study follows people with pulmonary arterial hypertension (PAH) to see how safe and effective ralinepag is over the long term. It may help your care team understand what to expect from continued treatment and monitoring.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Hershey, PennsylvaniaAges 40 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07151768Recruiting
Validating a risk score for lung disease patients with pulmonary hypertension
This study is testing whether a new risk score can better predict outcomes for people who have both chronic lung disease and pulmonary hypertension (high blood pressure in the lungs). If you qualify, the researchers will follow your health over time to see how well the score works.
Philadelphia, PennsylvaniaAges 18–99 - NCT07366034RecruitingPhase 3
Testing nerandomilast for children with lung scarring
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Philadelphia, PennsylvaniaAges 2–17 - NCT07179380RecruitingPhase 3
A study of an inhaled drug for lung disease with high blood pressure
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
Philadelphia, PennsylvaniaAges 18 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Philadelphia, PennsylvaniaAges 21 years+ - NCT06911632Recruiting
AI-assisted check for pulmonary hypertension in interstitial lung disease
This study uses an AI tool to help doctors decide if you should be tested for pulmonary hypertension (high blood pressure in the lungs), which can be a complication of interstitial lung disease. If the tool suggests you might have it, you may get an echocardiogram (an ultrasound of the heart) and a right heart catheterization (a test to measure pressure in the heart) to find out for sure.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07175038RecruitingPhase 2
Study of a new pill for pulmonary hypertension
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Philadelphia, PennsylvaniaAges 18–80 - NCT04543461Recruiting
Lung health study for young adults in the U.S.
This study follows young adults to learn about lung health and risk factors. It may help researchers better understand how breathing symptoms and exposures affect future lung outcomes.
Philadelphia, PennsylvaniaAges 25–35 - NCT04930289Enrolling by invitation
Lung transplant registry for better donor lung preservation
This study builds a worldwide database to track and improve how donor lungs are preserved before transplant. Your information may help doctors choose and manage donor lungs more effectively.
Philadelphia, PennsylvaniaAges Any age - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Philadelphia, PennsylvaniaAges 40 years+ - NCT07714252Enrolling by invitation
Virtual palliative care team for veterans with heart or lung disease
This study tests a virtual team of nurses and social workers who provide palliative care to veterans with heart failure, COPD, or interstitial lung disease. The goal is to improve quality of life by offering extra support at home.
Lebanon, PennsylvaniaAges 18 years+ - NCT06177717Recruiting
Lung Health Study for Young Adults
This study looks at how young adults' lungs work over time. It is a research visit where you'll complete breathing and other health tests to help understand lung health in people aged 25–35.
Pittsburgh, PennsylvaniaAges 25–35 - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06716606RecruitingPhase 3
Long-term safety of belimumab for lung disease in scleroderma and other connective tissue diseases
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03630211RecruitingPhase 2
Study of stem cell transplant for systemic sclerosis in youth
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Pittsburgh, PennsylvaniaAges 8–60 - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Hershey, PennsylvaniaAges 18 years+ - NCT07227376Recruiting
Collecting lung sounds with Eko digital devices
This study uses a digital stethoscope to record lung sounds from patients with and without breathing problems. It aims to help doctors better identify different types of lung sounds.
Philadelphia, PennsylvaniaAges Any age - NCT00258583Recruiting
ILD patient registry at UPMC Simmons Center
This study is a registry that collects information from adults with interstitial lung disease (ILD) who are seeking care at the UPMC Simmons Center. It helps the center learn about ILD and improve future treatment planning.
Pittsburgh, PennsylvaniaAges 18 years+
Lung Diseases trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting lung diseases studies listed above.
- Temple University Hospital · 10 studies
- University of Pennsylvania · 7 studies
- Thomas Jefferson University Hospital · 6 studies
- University of Pittsburgh Medical Center · 4 studies
- GSK Investigational Site · 3 studies
- Penn State Milton S Hershey Medical Center · 2 studies
- Temple Lung Center · 2 studies
- University of Pittsburgh · 2 studies
What taking part in a lung diseases study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung Diseases trials in other states
Common questions
- Are there lung diseases clinical trials in Pennsylvania?
- Yes. We're currently tracking 38 recruiting lung diseases studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung diseases study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung diseases trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung diseases studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.